On 7 November 2011, Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, announced that it had entered into a strategic partnership agreement with Oxford Gene Technology (OGT) aimed at improving the early detection of pancreatic cancer.

As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from individuals up to 7 years before the diagnosis of pancreatic cancer. OGT will apply its functional protein array platform and its Genefficiency™ microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both Abcodia and OGT will bring their expertise in experimental design and analysis.

Abcodia was advised on this transaction by Allistair Booth.